RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Nikkei 225 Hits Record High Above 56,000 After Japan Election Boosts Market Confidence 
U.S. Stock Futures Rise as Markets Brace for Jobs and Inflation Data 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
Oil Prices Slip as U.S.-Iran Talks Ease Middle East Tensions 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves 
Yen Slides as Japan Election Boosts Fiscal Stimulus Expectations 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Sanofi's Exclusive Negotiations with Clayton Dubilier & Rice
Sanofi (NASDAQ: SNY) announced on Monday that it has entered exclusive negotiations to sell a 50% controlling stake in its consumer health division, Opella, to the U.S. private equity firm Clayton Dubilier & Rice (CD&R). This strategic move reflects Sanofi's ongoing efforts to optimize its portfolio and focus on core operations.
Valuation and Investment Details
The Opella business is valued at approximately €16 billion ($17.38 billion), equating to 14 times its expected EBITDA for 2024. Additionally, the French public investment bank, Bpifrance, is anticipated to acquire a stake of around 2%, further solidifying the financial backing of this transaction.
Transaction Timeline and Approvals
The proposed sale is subject to definitive agreements and customary statutory approvals. If all goes according to plan, the transaction is expected to close by the second quarter of 2025 at the earliest, marking a significant milestone for both Sanofi and CD&R.
As the negotiations progress, stakeholders will be closely monitoring the developments surrounding this transaction, given its potential impact on Sanofi's market position and future growth strategies.
